Efficacy and safety of rivaroxaban compared to enoxaparin in treatment of cancer-associated venous thromboembolism
| Autor: | Robert D. McBane, James R. Cerhan, Rayya A. Saadiq, Stanislav Henkin, Charles J. Lenz, Waldemar E. Wysokinski, Charles L. Loprinzi, Haraldur Bjarnason, Paul R. Daniels, David O. Hodge, Sara J. Holton, Benjamin Simmons, Dalene M. Bott-Kitslaar, Ana I. Casanegra, Emily R. Vargas |
|---|---|
| Rok vydání: | 2018 |
| Předmět: |
Rivaroxaban
Chemotherapy medicine.medical_specialty medicine.drug_class business.industry Genitourinary system medicine.medical_treatment Cancer Low molecular weight heparin Hematology General Medicine 030204 cardiovascular system & hematology medicine.disease Thrombophilia 03 medical and health sciences 0302 clinical medicine Internal medicine medicine Cumulative incidence 030212 general & internal medicine business medicine.drug Cohort study |
| Zdroj: | European Journal of Haematology. 101:136-142 |
| ISSN: | 0902-4441 |
| Popis: | Background Low molecular weight heparin (LMWH) is the guideline-endorsed treatment for cancer-associated venous thromboembolism (cVTE). Study objectives were to compare the efficacy and safety of rivaroxaban and enoxaparin in cVTE. Methods Using a cohort study design, consecutive patients with cVTE (3/1/2013-7/31/2016), enrolled in the Mayo Thrombophilia Clinic Direct Oral Anticoagulants Registry, were compared to contemporary cancer patients receiving enoxaparin. The cumulative incidence of venous thromboembolism (VTE) recurrence, major and clinically relevant non-major bleeding, and survival were assessed at 3 and 12 months. Results Ninety-eight patients received rivaroxaban (51% female, mean age 63 ± 12 years) and 168 enoxaparin (34.5% female, mean age 62 ± 15 years). The most common cancers included gastrointestinal/pancreatic, genitourinary and hematologic cancers. More than half of patients had pulmonary emboli at presentation. More than half had metastases, and two-thirds were receiving chemotherapy. At 3 months, there were no differences in VTE recurrence (rivaroxaban 1.0% vs enoxaparin 4.2%; P = .15), major bleeding (rivaroxaban 5.1% vs enoxaparin 3.6%; P = .55), or all-cause mortality (rivaroxaban 4.1% vs enoxaparin 8.9%; P = .14). At 12 months, these outcomes did not differ by treatment strategy. Conclusion The results of this "real-world" experience with cVTE suggest that rivaroxaban may offer a safe and effective alternative to LMWH. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|